Xenical en afslanken


logo.jpg (7231 bytes)

Google

Deze pagina is verouderd - ontvang onze nieuwtjes per email

 

Xenical en kanker


Er was eens een fabrikant die met een wondermiddel op de markt kwam voor mensen met overgewicht. De markt reageerde positief op het nieuwe medicijn en de vele journalisten papagaaiden het goede nieuws weer door want is weer goed voor de oplages (weet u nog, de DNA afslankpil!).

Dus dacht de fabrikant laten we eens denken aan schaalvergroting en eens kijken naar een over de toonbank middel (zonder recept). De Amerikaanse keuringsdienst FDA zag geen problemen dus alles leek erop dat het Xenical sprookje een mooi einde zou krijgen.

Maar het sprookje werd bruut verstoord door de boze heks in de vorm van een Amerikaanse consumenten organisatie die het middel het liefst zo snel mogelijk ziet verdwijnen gezien de resultaten van de studies die werden gedaan door de fabrikant.

Het wondermiddel bleek toch wat minder fijne kantjes hebben die wat minder bekend waren bij het grote publiek dus blies deze organisatie het mooie sprookje uit en komt het medicijn nu op een heel andere manier in het middelpunt van de belangstelling.

De FDA wordt blijkbaar ook weer eens in zijn hemd gezet en ligt wederom onder vuur. Volgens deze organisatie is aspartaam niet schadelijk, kan kwik in vaccins geen kwaad maar kwik in vis wel, en moest het feit dat er in limonade met extra vitamine C benzeen kan zitten 15 jaar worden stilgehouden. Dus het sprookje zal waarschijnlijk geen leuk einde krijgen voor de farmaceuten die toch al zo onder vuur liggen.

In het verleden heeft de consumenten organisatie Public Citizen ook al jaren eerder gewaarschuwd voordat medicijnen zoals Vioxx, Ephedra, Bextram, Baycol, Rezuline van de markt werden gehaald na oa veel druk van consumenten.

Ron


Petition to the FDA to immediately remove the diet drug orlistat (XENICAL) from the market

April 10, 2006

Andrew Von Eschenbach, M.D., Acting Commissioner
U.S. Food and Drug Administration
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Dear Dr. Von Eschenbach:

Public Citizen, representing more than 100,000 consumers nationwide, hereby petitions the Food and Drug Administration (FDA) pursuant to the Federal Food, Drug and Cosmetic Act 21 U.S.C. Section 355(e)(3), and 21 C.F.R. 10.30, to immediately remove from the market, the prescription version of Xenical (orlistat, Roche Pharmaceuticals). This drug, which treats obesity, causes a significant increase in the incidence of aberrant crypt foci, which are widely believed to be a precursor of colon cancer.[1],[2] This finding makes it even clearer how ill-advised switching orlistat to OTC status would be, something FDA is currently considering. (An “approvable” letter, meaning FDA will approve the drug if certain conditions are met, is said to have been sent by the FDA to Glaxo—the manufacturer of the OTC version---in the past several days.) We are joined in this petition by Dr. Theresa Pretlow, Professor of Pathology and by Dr. Thomas Pretlow, Professor in the Departments of Pathology, Urology, Oncology, and Environmental Health Sciences at Case Western Reserve School of Medicine. Their research, consisting of some 42 papers on colorectal cancer including 15 specifically on aberrant crypt foci, has helped to establish the relationship between aberrant crypt foci and colon cancer.

As Director of the National Cancer Institute, which has funded a substantial portion of the work by Drs. Pretlow establishing the link between ACF and colon cancer, you have repeatedly talked about preventing death and suffering from cancer. The failure to ban the prescription version of this drug or, worse, to make it much more widely available by allowing OTC sales, is a decision that is likely to increase cancer incidence.

http://www.citizen.org/publications/release.cfm?ID=7423


Roche Meeting with Stiff Opposition to Its Efforts to Market Xenical as an OTC Diet Drug

Pharmaceutical giant Roche Holding AG had hoped for a smooth approval of Xenical as the first over-the-counter (OTC) weight-loss drug. Xenical is manufactured by Roche Pharmaceuticals (a unit of Roche Holding AG) and is the higher-dose version of the OTC spin-off that will be sold under the name orlistat. Once an FDA advisory committee had voted 11-3 to recommend the OTC version of Xenical for marketing, Roche had assumed final approval was assured. Now, however, that pathway seems less sure.

http://www.newsinferno.com/archives/1078


Xenical Fat Blocker and Cancer Risks

According to new research, fat blocker, Xenical has been allegedly linked to aberrant crypt foci (ACF), the earliest sign of colon cancer. During initial clinical trials, Xenical also showed an increased risk of breast cancer and vitamin deficiency. Xenical (orlistat) is a pharmaceutical drug used to help obese or overweight adults and children lose weight by blocking and preventing fatty food from being digested. Xenical is prescribed to patients with a body mass index of 27 or more. Essentially, it blocks one-third of the fat from being absorbed into the body.

http://www.lawyersandsettlements.com/case/xenical_cancer


Consumer group calls for Xenical withdrawal

The petition, which was also signed by Theresa Pretlow and Thomas Pretlow, both pathology professors at Case Western Reserve School of Medicine, has cited two studies that showed those patients on Xenical lost about 13 pounds while those not receiving the drug lost seven pounds. It described orlistat as “a drug that has shown minimal efficacy coupled with a still unresolved potential to cause breast and colon cancer”.

http://www.pmlive.com/pharm_market.cfm?show
Article=1&ArticleID=4538


Details: Theresa P. Pretlow, Ph.D. (Professor)

Mailing Address:
10900 Euclid Ave.
Cleveland, OH 44106-7288
Tel (216) 368-8702
theresa.pretlow@case.edu

http://www.cwru.edu/med/pathology/fac/pretlow_ter.html

Dr Theresa Pretlow is interested in the development of cancer, i.e., the changes that take place during the transformation of normal cells to malignant ones. Aberrant crypt foci (ACF) are lesions that were first identified microscopically in unembedded colons from rodents as soon as 2 weeks after a single dose of carcinogen. Her laboratory was the first to report these lesions in the macroscopically normal colonic mucosa of humans. The frequency of these lesions is increased in patients with colon cancers compared to those without colon cancer and in patients with hereditary conditions such as familial adenomatous polyposis (FAP) compared with patients with sporadic colon cancer.


Links

http://www.usatoday.com/news/health/2006-04-10-xenical-otc_x.htm


 

 


 


View My Stats